Holen Sie sich die Stockscreener-App
5.80
5.45%
0.30
Handel nachbörslich:
5.55
-0.25
-4.31%
Schlusskurs vom Vortag:
$5.50
Offen:
$5.5
24-Stunden-Volumen:
3.32M
Relative Volume:
1.24
Marktkapitalisierung:
$930.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-206.69M
KGV:
-4.2789
EPS:
-1.3555
Netto-Cashflow:
$-186.49M
1W Leistung:
+16.94%
1M Leistung:
+12.40%
6M Leistung:
+82.39%
1J Leistung:
+243.20%
1-Tages-Spanne:
$5.46
$5.935
1-Wochen-Bereich:
$5.13
$6.10
52-Wochen-Spanne:
$1.285
$7.18
Annexon Inc Stock (ANNX) Company Profile
Firmenname
Annexon Inc
Sektor
Branche
Telefon
(650) 822-5500
Adresse
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
5.80 | 882.61M | 0 | -206.69M | -186.49M | -1.3555 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-30 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-05-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-09-16 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | BTIG Research | Buy |
| 2021-11-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-09-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-26 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | BofA Securities | Buy |
| 2020-08-18 | Eingeleitet | Cowen | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Annexon Inc Aktie (ANNX) Neueste Nachrichten
Annexon (NASDAQ:ANNX) Shares Up 6.6%What's Next? - MarketBeat
Wall Street analysts see a 165.52% upside in Annexon (ANNX): Can the stock really move this high? - MSN
HC Wainwright Estimates Annexon FY2030 Earnings - MarketBeat
Annexon posts full-year 2025 financial results and portfolio updates - Traders Union
H.C. Wainwright Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Dip Buying: Can Annexon Inc reach all time highs this yearTrade Exit Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - Sahm
Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High? - Yahoo Finance
Multiple Insiders Sold Annexon Shares Presenting Weak Signs For Investors - 富途牛牛
Wells Fargo Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Cyber Risks Threaten Annexon Biosciences’ Clinical Operations, Reputation and Financial Health - tipranks.com
Big Picture: What are the risks of holding Annexon IncEarnings Growth Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Jefferies reiterates Annexon Biosciences stock rating on M&A activity By Investing.com - Investing.com Canada
Annexon (ANNX) Gains Attention Amid Pharma Deal Activity - gurufocus.com
Annexon (NASDAQ:ANNX) Shares Gap UpShould You Buy? - MarketBeat
Needham Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Annexon Reports Positive Q4 and Full-Year 2025 Results, Highlights Key Milestones - National Today
TD Cowen Maintains Annexon(ANNX.US) With Buy Rating - Moomoo
Annexon Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Annexon (ANNX) Advances in Neuroinflammation Treatments - gurufocus.com
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - Investing News Network
Annexon (NASDAQ:ANNX) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Annexon (NASDAQ: ANNX) advances C1q-targeted drugs for GBS and GA - Stock Titan
Annexon (NASDAQ: ANNX) widens 2025 loss but extends cash runway into 2027 - Stock Titan
Annexon Reports Fourth Quarter and Year-End 2025 Financial - globenewswire.com
U.S. Earnings Preview: Before Market Open March 30 - Moomoo
ANNX Should I Buy - Intellectia AI
Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Vanguard disaggregates holdings; Annexon (ANNX) shows 0 shares reported - Stock Titan
Annexon (NASDAQ:ANNX) Trading Up 10.2%What's Next? - MarketBeat
Insider Sell: Will Annexon Inc be affected by tariffs2026 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn
Are Healthcare Stocks Falling Behind American Well (AMWL) in Performance This Year? - Bitget
Are Medical Stocks Lagging American Well (AMWL) This Year? - Yahoo Finance
U.S. Earnings Preview: Before Market Open March 23 - Moomoo
If You Invested $1,000 in Annexon, Inc. (ANNX) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX) and Electrocore (ECOR) - The Globe and Mail
ANNX PE Ratio & Valuation, Is ANNX Overvalued - Intellectia AI
Annexon, Inc. (ANNX) Discusses Vision Preservation in Geographic Atrophy With C1q Inhibition and Key Insights From ARCHER TrialsSlideshow (NASDAQ:ANNX) 2026-03-20 - Seeking Alpha
Chardan Capital Maintains Buy Rating on Annexon (ANNX) with $16 - GuruFocus
Annexon's (ANNX) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
H.C. Wainwright reiterates Buy on Annexon stock, $14 target By Investing.com - Investing.com Canada
Annexon Inc to Host KOL Event Transcript - gurufocus.com
ANNX Earnings History & Surprises | EPS & Revenue Results | ANNEXON INC (NASDAQ:ANNX) - ChartMill
Annexon Investor Day: ANX007 Targets C1q in Dry AMD GA as Phase III Readout Nears Q4 - MarketBeat
ANNX: Phase III trial for C1q inhibition in GA is fully enrolled, with results expected in Q4 - TradingView
ANNX: Phase III trial for C1q inhibition in GA targets vision preservation with robust clinical design - TradingView
Portfolio Update: Will Annexon Inc benefit from government policyWeekly Stock Summary & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Annexon reports inducement grant to new employee under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ANNX SEC FilingsAnnexon, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Wall Street Recap: Is Annexon Inc in a bullish channel2026 Macro Moves & Technical Confirmation Alerts - baoquankhu1.vn
Finanzdaten der Annexon Inc-Aktie (ANNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Annexon Inc-Aktie (ANNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dananberg Jamie | CHIEF MEDICAL OFFICER |
Mar 02 '26 |
Sale |
5.43 |
5,820 |
31,603 |
123,582 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Mar 02 '26 |
Sale |
5.42 |
4,339 |
23,517 |
182,625 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Mar 02 '26 |
Sale |
5.42 |
5,566 |
30,168 |
154,161 |
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Sale |
5.43 |
5,894 |
32,004 |
180,093 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
5.42 |
5,565 |
30,162 |
170,700 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):